The Sidney Kimmel Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Leading Cancer Centers Form AI Alliance with $40M Tech Industry Backing to Revolutionize Cancer Research
• Four major NCI-designated cancer centers, including Dana-Farber and Memorial Sloan Kettering, have united to form the Cancer AI Alliance (CAIA) with $40 million in funding from tech giants AWS, Microsoft, NVIDIA, and Deloitte.
• The alliance will utilize federated AI learning to analyze vast amounts of cancer data while maintaining privacy, enabling researchers to uncover new insights in tumor biology and treatment resistance.
• CAIA, coordinated by Fred Hutch Cancer Center, aims to begin operations by end of 2024 with first insights expected by 2025, targeting an ambitious goal of $1 billion in resources over time.
Phase 2 Trial Launched to Target Minimal Residual Disease in AML with Revumenib and Venetoclax
• Break Through Cancer initiates a Phase 2 trial to evaluate the combination of revumenib and venetoclax in eradicating minimal residual disease (MRD) in acute myeloid leukemia (AML).
• The trial aims to determine if clearing MRD with the drug combination correlates with longer progression-free survival in AML patients.
• Revumenib, a menin inhibitor, and venetoclax, a BCL2 inhibitor, are being investigated for their synergistic potential in eliminating residual leukemia cells.
• The study will also explore biomarkers to predict drug response and refine methods for measuring and understanding MRD in AML.
Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC
• Perioperative nivolumab significantly extends event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), with a median EFS increase from 17.0 to 40.1 months.
• Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR).
• Circulating tumor DNA (ctDNA) clearance during neoadjuvant therapy is a potential biomarker, with higher clearance rates observed in patients receiving nivolumab and correlating with improved outcomes.
• Biomarker analysis suggests PD-L1 positivity may predict better EFS with nivolumab monotherapy, while KRAS co-mutations may benefit more from nivolumab plus ipilimumab combination therapy.
Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC
• Perioperative nivolumab significantly extends event-free survival (EFS) in resectable NSCLC, with a median EFS increase from 17.0 to 40.1 months.
• Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR).
• Circulating tumor DNA (ctDNA) clearance during neoadjuvant therapy is a potential biomarker, with higher clearance rates observed in the nivolumab group and correlation with PCR achievement.
• Biomarker analysis suggests PD-L1 positivity may predict better EFS with nivolumab monotherapy, while KRAS co-mutations may benefit more from nivolumab plus ipilimumab.
Radionuclide Therapy Shows Promise in Advanced Prostate Cancer Treatment
• Radionuclide therapies are emerging as promising options for treating metastatic castration-resistant prostate cancer (mCRPC), especially after resistance to standard treatments.
• Lutetium-177 PSMA-617 (Lu-PSMA-617) has demonstrated overall survival benefits in mCRPC patients, leading to FDA and EMA approvals for PSMA-positive cases.
• Ongoing clinical trials are exploring Lu-PSMA-617 in earlier stages of prostate cancer and in combination with other therapies like androgen deprivation and immunotherapy.
• Targeted alpha therapy using Actinium-225 labeled PSMA ligands shows potential for improved outcomes, particularly in patients who do not respond to Lutetium-177 based treatments.
© Copyright 2025. All Rights Reserved by MedPath